Compare ASTI & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | XLO |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 39.4M |
| IPO Year | 2014 | 2021 |
| Metric | ASTI | XLO |
|---|---|---|
| Price | $6.55 | $8.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 669.8K | 34.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,398,149.00 | ★ $43,766,000.00 |
| Revenue This Year | N/A | $88.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 163.25 | ★ 589.88 |
| 52 Week Low | $1.30 | $0.46 |
| 52 Week High | $9.87 | $9.25 |
| Indicator | ASTI | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 81.61 |
| Support Level | $1.68 | $0.62 |
| Resistance Level | $7.10 | $9.22 |
| Average True Range (ATR) | 0.75 | 0.47 |
| MACD | 0.17 | -0.25 |
| Stochastic Oscillator | 72.47 | 48.37 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.